MX375356B - Composiciones efectivas contra la conjuntivitis viral. - Google Patents

Composiciones efectivas contra la conjuntivitis viral.

Info

Publication number
MX375356B
MX375356B MX2016009475A MX2016009475A MX375356B MX 375356 B MX375356 B MX 375356B MX 2016009475 A MX2016009475 A MX 2016009475A MX 2016009475 A MX2016009475 A MX 2016009475A MX 375356 B MX375356 B MX 375356B
Authority
MX
Mexico
Prior art keywords
against viral
compositions against
effective compositions
viral conjunctivitis
subtype
Prior art date
Application number
MX2016009475A
Other languages
English (en)
Other versions
MX2016009475A (es
Inventor
Andreas Grassauer
Angelika Bodenteich
Christiane Koller
Eva Prieschl-Grassauer
Frederic Pilotaz
Marielle König-Schuster
Martina Morokutti-Kurz
Sabine Nakowitsch
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of MX2016009475A publication Critical patent/MX2016009475A/es
Publication of MX375356B publication Critical patent/MX375356B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para usarse como un medicamento en el tratamiento tópico profiláctico o terapéutico de infecciones oculares causadas por el adenovirus del subtipo D o el virus de la influenza A del subtipo H7; la composición en su formulación lista para usarse comprende iota-carragenano como un ingrediente antiviral activo y está sustancialmente libre de una sal de haluro metálico o contiene no más de 0.5% p/v de una sal de haluro metálico.
MX2016009475A 2014-01-22 2015-01-20 Composiciones efectivas contra la conjuntivitis viral. MX375356B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14152188.0A EP2898888B8 (en) 2014-01-22 2014-01-22 Composition comprising iota-carrageenan against viral Conjunctivitis
PCT/EP2015/051015 WO2015110429A1 (en) 2014-01-22 2015-01-20 Composition effective against viral conjunctivitis

Publications (2)

Publication Number Publication Date
MX2016009475A MX2016009475A (es) 2017-01-16
MX375356B true MX375356B (es) 2025-03-06

Family

ID=49956098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009475A MX375356B (es) 2014-01-22 2015-01-20 Composiciones efectivas contra la conjuntivitis viral.

Country Status (15)

Country Link
US (1) US10220055B2 (es)
EP (2) EP2898888B8 (es)
JP (1) JP6635343B2 (es)
CN (1) CN105939720B (es)
CA (1) CA2937402C (es)
DK (1) DK2898888T3 (es)
ES (2) ES2734269T3 (es)
HR (1) HRP20191050T1 (es)
HU (1) HUE044329T2 (es)
MX (1) MX375356B (es)
PL (1) PL2898888T3 (es)
PT (1) PT2898888T (es)
RS (1) RS58731B1 (es)
SI (1) SI2898888T1 (es)
WO (2) WO2015110430A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102789464B1 (ko) * 2015-09-25 2025-04-03 오코겐, 인크. 란피르나제 및/또는 암피나제를 사용하는 바이러스성 결막염의 치료
WO2021198908A1 (en) * 2020-04-01 2021-10-07 Minas Theodore Coroneo Ophthalmic compositions for treating coronaviruses
UY39313A (es) * 2020-07-03 2022-01-31 Phoxgen Ltd Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire
EP4623919A1 (en) * 2024-03-28 2025-10-01 Marinomed Biotech AG Composition comprising iota-carrageenan for the treatment of dry eyes, non-viral conjunctivitis and allergic ocular conditions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783446A (en) * 1985-11-22 1988-11-08 Neushul Mariculture Incorporated Method for the treatment of AIDS virus and other retroviruses
FR2653021A1 (fr) * 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
DE69212850T2 (de) * 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
IT1313610B1 (it) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
DE10352137A1 (de) 2003-11-04 2005-06-16 Beschorner, Katharina, Dr. Verwendung sulfatierter Hyaluronsäure
DE102005046769A1 (de) 2005-09-29 2007-04-05 Berlin-Chemie Ag Lichtstabile, brivudinhaltige pharmazeutische Formulierung zur Behandlung von Augenherpes (Herpes Ophthalmicus)
WO2007133034A2 (en) * 2006-05-13 2007-11-22 Lg Electronics Inc. Method of performing procedures for initial network entry and handover in a broadband wireless access system
NZ577063A (en) * 2006-12-05 2011-05-27 Marinomed Biotechnologie Gmbh Use of iota-carrageenan for treating rhinovirus infections
JP5647518B2 (ja) 2007-08-24 2014-12-24 マリノメド バイオテクノロジー ゲゼルシャフト ミット ベシュレンクテル ハフツング 硫酸化多糖を含有する抗ウイルス性組成物
US9481856B2 (en) 2008-06-09 2016-11-01 Bausch & Lomb Incorporated Pharmaceutical formulations comprising stabilized polysaccharides and source of hydrogen peroxide
PL2303287T3 (pl) * 2008-07-01 2014-05-30 Marinomed Biotechnologie Gmbh Przeciwalergiczne biopolimery pochodzenia morskiego
US20100086512A1 (en) 2008-10-02 2010-04-08 Rolf Schaefer Mucomimetic compositions and uses therefore
SG181421A1 (en) 2009-12-22 2012-07-30 Marinomed Biotechnologie Gmbh Synergistic antiviral composition and use thereof
US9161923B2 (en) * 2010-07-02 2015-10-20 Brien Holden Vision Institute Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
CN102988280B (zh) * 2012-10-08 2014-03-19 新乡医学院 一种加雷沙星滴眼剂

Also Published As

Publication number Publication date
EP3096766B1 (en) 2020-02-26
RS58731B1 (sr) 2019-06-28
EP2898888A1 (en) 2015-07-29
WO2015110429A1 (en) 2015-07-30
CA2937402A1 (en) 2015-07-30
PT2898888T (pt) 2019-07-16
JP2017503841A (ja) 2017-02-02
ES2734269T3 (es) 2019-12-05
CA2937402C (en) 2022-07-12
JP6635343B2 (ja) 2020-01-22
ES2791360T3 (es) 2020-11-04
DK2898888T3 (da) 2019-06-03
MX2016009475A (es) 2017-01-16
US20160331776A1 (en) 2016-11-17
WO2015110430A1 (en) 2015-07-30
CN105939720A (zh) 2016-09-14
EP3096766A1 (en) 2016-11-30
EP2898888B8 (en) 2019-06-12
HUE044329T2 (hu) 2019-10-28
SI2898888T1 (sl) 2019-06-28
EP2898888B1 (en) 2019-04-24
US10220055B2 (en) 2019-03-05
CN105939720B (zh) 2020-01-31
PL2898888T3 (pl) 2019-09-30
HRP20191050T1 (hr) 2019-09-06

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
EA201890196A1 (ru) Композиция для устранения заложенности носа, обладающая противовирусным действием
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
JOP20170135A1 (ar) مركبات ديازاسبيروألكيل مثيل-إندول
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201590457A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201690962A1 (ru) Составы
MX373678B (es) Composición farmacéutica de clorhidrato de s-cetamina.
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
EA201590862A1 (ru) Фармацевтические композиции
MX394588B (es) Composición farmacéutica.
EA201492091A1 (ru) Фармацевтические композиции для местного применения, содержащие тербинафид и мочевину
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
EA201790495A1 (ru) Фармацевтические композиции длительного действия
MX375356B (es) Composiciones efectivas contra la conjuntivitis viral.
BR112016007526A2 (pt) formulação de tratamento contra hiv de atazanavir e cobicistat
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
ZA201906153B (en) Pharmaceutical compositions for combination therapy
BR112018012947A2 (pt) composições para higiene pessoal
MX2015012575A (es) Novedosos derivados de acrilamida como agentes contra la malaria.

Legal Events

Date Code Title Description
FG Grant or registration